The CDC warns that Covid-19 vaccines may not protect immunocompromised people

[ad_1]

“People who are immunocompromised should be advised about the potential to reduce immune responses to COVID-19 vaccines and to follow current prevention measures (including wearing a mask, staying 6 feet away from others they do not live with, and avoiding crowded and poorly ventilated indoor spaces) to protect themselves from COVID-19 until the healthcare provider is notified otherwise,” according to the CDC website.

The CDC did not go so far as to tell millions of immunocompromised people in the United States to get an extra dose of the Covid-19 vaccine, noting that “the safety, efficacy, and benefit of additional doses of COVID-19 vaccines in people who are deficient Immunity is still being evaluated.”

“The CDC is looking at ongoing research exploring the possibility that immunodeficiency could benefit from an additional dose,” a federal official told CNN.

Some immunocompromised people have, on their own, received extra doses of the vaccine, and a study by Johns Hopkins researchers suggested last month that an extra dose might help increase levels of Covid-19 antibodies for some transplant recipients who didn’t have a complete response. their original vaccines.

On Sunday, Dr. Anthony Fauci, President Joe Biden’s chief medical advisor, acknowledged the fact that some people act ahead of official recommendations, noting that there are individual doctors “now saying, ‘I want to go the extra mile with someone who may have a lower level of immunity. ”

On Friday, the CDC said data suggests that response to vaccines may decline for several groups, including organ transplant recipients, people receiving chemotherapy for cancer, people with some types of leukemia, and people on dialysis or taking Some drugs that inhibit. immune system.

The Centers for Disease Control and Prevention’s Immunization Practices Advisory Committee is scheduled to discuss additional doses for immunocompromised individuals during its July 22 meeting.

Michael Needleman contributed to this report.

.

[ad_2]